title: Efficacy, Safety, and Interactions of a Live Infectious Bursal Disease Virus Vaccine for Chickens Based on Strain IBD V877.
abstract: Infectious bursal disease (IBD) is a highly contagious disease in young chickens which can result in high morbidity and mortality and also in great economic losses. The main target for the virus is the lymphoid tissue with a special predilection for the bursa of Fabricius. Several vaccines are available to control the disease. Intermediate plus vaccines are used in chickens with high maternal antibody titers which face high infection pressure. An example of an intermediate plus vaccine is a live vaccine based on IBD strain V877. The results of an efficacy study in commercial broilers with different levels of maternally derived antibodies (MDA) showed that the V877-based IBD vaccine can break through maternal antibody titers of higher than 1100 as determined by an IBD ELISA. The safety of the vaccine was demonstrated in a study in which specific-pathogen-free (SPF) chickens were vaccinated with a tenfold dose of the vaccine strain and a tenfold dose of the vaccine strain after five back passages in SPF chickens. The vaccine virus caused lesions, as could be expected for an intermediate plus vaccine, but the scores were not much higher than the maximal scores allowed for mild IBD vaccines in the European Pharmacopoeia, and reversion to virulence was absent. In studies in SPF chickens, there were no negative impacts by the IBD V877 vaccine on the efficacy of a live QX-like IB vaccine and a live Newcastle disease La Sota vaccine in vaccination challenge studies, although the IBD vaccine had a negative effect on the antibody response generated by the QX-like IB vaccine. It is concluded that the IBD V877 vaccine has the capacity to break through high levels of MDA, has a satisfactory safety profile, and interactions with other live vaccines are limited. In order to limit bursal lesions after vaccination it is recommended to confirm the presence of MDA before vaccinating with the V877 vaccine.
authors: Harm J
authors: HJ
authors: Geerligs
authors: Ellen
authors: E
authors: Ons
authors: Gert Jan
authors: GJ
authors: Boelm
authors: Dieter
authors: D
authors: Vancraeynest
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D018175:Birnaviridae Infections / Q000276:immunology / Q000662:veterinary* / Q000821:virology; D002645:Chickens; D007112:Immunity, Maternally-Acquired; D007243:Infectious bursal disease virus / Q000145:classification* / Q000472:pathogenicity; D013047:Specific Pathogen-Free Organisms; D014613:Vaccines, Attenuated; D014765:Viral Vaccines / Q000009:adverse effects / Q000276:immunology*; D014774:Virulence
chemical_list: D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines